Telmisartan and hydrochlorothiazide

Name: Telmisartan and hydrochlorothiazide
Creator: U.S. Department of Health & Human Services
License: 暂无描述

data.gov2026-03-14 收录

下载链接：

https://catalog.data.gov/dataset/telmisartan-and-hydrochlorothiazide

下载链接

链接失效反馈

官方服务：

资源简介：

Telmisartan and Hydrochlorothiazide is a prescription oral tablet combining two medications: telmisartan, an angiotensin II receptor blocker, and hydrochlorothiazide,...

提供机构：

U.S. Department of Health & Human Services

Telmisartan and Hydrochlorothiazide Drug Market

The report on Telmisartan and Hydrochlorothiazide Drug covers a summarized study of several factors supporting market growth, such as market size, market type, major regions, and end-user applications

IMR REPORTS20

Global Telmisartan Hydrochlorothiazide Tablets Market Competitive Environment 2026-2033

The Telmisartan Hydrochlorothiazide Tablets market has experienced significant growth in recent years, driven primarily by the rising prevalence of hypertension and cardiovascular diseases worldwide.

STATSndata00

Dataset from An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg, Followed by a 52 Weeks Extension Study to Assess Long Term Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg

This is a multi-centre, randomised, double-blind, active-controlled, parallel-group comparative trial to compare the fixed dose combination (FDC) of telmisartan 80 mg + hydrochlorothiazide 12.5 mg and

NIAID Data Ecosystem00

North America Telmisartan and Hydrochlorothiazide Drug Market

The report on North America Telmisartan and Hydrochlorothiazide Drug covers a summarized study of several factors supporting market growth, such as market size, market type, major regions, and end-use

IMR REPORTS10

Dataset from A Prospective Randomised Study to Compare a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 25 mg With a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg in Patients With Uncontrolled Hypertension Who Fail to Respond Adequately to Treatment With a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg

The primary objective of this trial is to demonstrate that a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 25 mg (T80/H25) is superior in reducing blood pressure after eight wee

NIAID Data Ecosystem00